News from the BioCity Campus

Action paper NanoBioMedizin 2020 published

In order to ensure competitive research, development and market launch of advanced materials and especially nanomaterials in Germany, the action paper NanoBioMedizin 2020 names and defines the main challenges, topics with a high need for research and development as well as important areas of action to improve patient care.
“In diagnostics, this includes, for example, the prevention and early detection of diseases, which can be achieved by researching new biomarkers and more sensitive sensor systems, such as lab-on-a-chip systems, but which must be robust, inexpensive and standardisable. Another very important field of action is the translation and thus the transfer of research results into practical application, which requires better training of specialists, new funding and financial models as well as harmonized European regulation.« explains Dr. Nils Bohmer, Project Manager Research and Project Coordination DECHEMA eV

Forecasts by the Institute for Health Research (IGSF) predict a steady increase in the annual number of new cases of cardiovascular diseases, age-related diabetes mellitus, osteoporosis, arthrosis, tumors, strokes and dementia. Recognizing these diseases more quickly and treating them more effectively should be among the most urgent medical and social goals. NanoBioMedizin helps to identify the concrete clinical challenges that exist in various diseases and shows how these can be solved by nanobiomedical innovations in diagnostics, therapy or regenerative medicine and which important fields of action exist for this.

The action paper provides a detailed analysis of the conditions for the translation of relevant research results as well as recommendations for action to optimize research and development. Furthermore, the paper deals with clinical issues and nanobiomedical research approaches, particularly with in-vivo and in-vitro diagnostics. Since the social and economic challenges should not be neglected, the expert authors from more than 15 research institutions, pharmaceutical companies and clinics also address this problem in the chapter "Vision 2050 and socio-economic effects" and show that topics such as medical patient relationship of the future or new calculation models for the adjustment of the reimbursement systems will be relevant for your research.

The goals continue to be to create new interdisciplinary research, training and translation structures that involve scientists, technologists, clinicians and SMEs and effectively network with larger industrial companies and regulatory authorities. Overall, the goal is to establish complete nanobiomedical value chains in Germany in order to enable the economic use of nanobiomedicine in Germany in the long term.

The Action Paper 2020 is a further developed version of the paper from 2015. The German Platform NanoBioMedicine was founded in 2015 by representatives from research institutions, industry and authorities. The aim of the initiative is to bring the results of nanobiotechnological research to patients more quickly and effectively and to make Germany scientifically and economically fit for global competition in the future technology of nanobiomedicine.

Source: Press release DECHMA from December 02.12.2020nd, XNUMX

previous news

Saxony lifts application freeze for research and development projects

Technology funding from the European Regional Development Fund (ERDF): Since the start of the funding period in 2014, the Free State has approved grants totaling 486 million euros. From now on, Saxon companies can again submit R&D project applications with a maximum duration of 2021 months to the SAB until the end of January 18.


IQ Innovation Award Central Germany 2021 started with digital live event

With a digital kickoff in front of around 100 spectators, the IQ Innovation Award Central Germany 2021 officially started on Wednesday. Until March 15, 2021, applications can be submitted in five central German key sectors for the cluster innovation competition in the central German metropolitan region.